The page below is a sample from the LabCE course Emerging Cardiovascular Risk Markers. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Emerging Cardiovascular Risk Markers (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 97 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart

Lipoprotein-Associated Phospholipase A2 (LpPLA2)

LpPLA2, or platelet-activating factor acetylhydrolase, is a lipase enzyme found predominantly on the surface of LDL particles. Note that LpPLA2 is not an apolipoprotein. LpPLA2 is made by inflammatory cells (T cells, mast cells, macrophages) and is then integrated onto the surface of lipoprotein particles. The enzymatic function of LpPLA2 is to hydrolyze oxidized phospholipids in LDL.

LpPLA2 plays a corrective role in removing oxidized phospholipids. Thus, it might seem that having high levels of LpPLA2 would be good. However, although LpPLA2 has a positive role in removing oxidized lipids, it also generates inflammatory products in the process. So high levels of LpPLA2 are actually associated with increased cardiovascular risk. Researchers have identified high amounts of LpPLA2 in human atherosclerotic lesions. The LpPLA2 that accumulates in the vessel wall can come from LDL (which can carry LpPLA2 on its surface) or it can come from immune cells that have invaded the vessel wall. Since LpPLA2 is produced or localized in the plaque itself, it may be a more specific marker of cardiovascular function compared to systemic, more general inflammatory markers like hs-CRP.